United Therapeutics (UTHR) Expected to Announce Earnings on Wednesday

United Therapeutics (NASDAQ:UTHR) is expected to be posting its Q3 2025 results before the market opens on Wednesday, October 29th. Analysts expect United Therapeutics to post earnings of $6.75 per share and revenue of $812.8730 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 9:00 AM ET.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same period in the previous year, the firm posted $5.85 earnings per share. The business’s revenue for the quarter was up 11.7% on a year-over-year basis. On average, analysts expect United Therapeutics to post $24 EPS for the current fiscal year and $27 EPS for the next fiscal year.

United Therapeutics Stock Performance

Shares of UTHR opened at $421.04 on Tuesday. The company’s 50 day moving average price is $399.53 and its 200 day moving average price is $333.88. United Therapeutics has a 52 week low of $266.98 and a 52 week high of $459.48. The company has a market capitalization of $18.99 billion, a PE ratio of 16.43, a PEG ratio of 4.56 and a beta of 0.66.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research report on Wednesday, September 10th. Jefferies Financial Group boosted their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Bank of America boosted their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a research report on Tuesday, September 2nd. Royal Bank Of Canada began coverage on shares of United Therapeutics in a research note on Friday, September 26th. They set an “outperform” rating and a $569.00 price target on the stock. Finally, UBS Group increased their price target on shares of United Therapeutics from $560.00 to $580.00 and gave the stock a “buy” rating in a research note on Monday, September 29th. Nine research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $461.62.

Insider Buying and Selling

In related news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $427.41, for a total transaction of $9,616,725.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction on Thursday, October 16th. The stock was sold at an average price of $431.50, for a total transaction of $4,746,500.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $15,871,001.50. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 326,935 shares of company stock valued at $135,057,522. Company insiders own 10.30% of the company’s stock.

Institutional Trading of United Therapeutics

Large investors have recently modified their holdings of the company. WealthCollab LLC raised its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. raised its stake in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its stake in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the last quarter. Geneos Wealth Management Inc. raised its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. Finally, Bank of Nova Scotia raised its stake in United Therapeutics by 6.9% during the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 105 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.